Kinfo
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd.

NRSNNASDAQHealthcare·US · USD
$4.03
+0.10 (+2.41%)
Prices as of October 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap7.64M USD
Enterprise value6.96M USD
Trailing P/E-9.34
Forward P/E-0.33
PEG ratio-0.33
Price / sales0.00
Price / book0.00
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-247.30%
Return on equity-2174.98%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-11.07M USD
Net income-11.13M USD
Diluted EPS-$47.10
Rev. growth (YoY)0.00%
Balance sheet
Total cash166.00K USD
Total debt170.00K USD
Debt / equity-0.11
Current ratio0.31
Book value / share-$0.96
Cash flow (TTM)
Operating cash flow-7.67M USD
Levered free cash flow-3.87M USD
Shares & price
Shares outstanding32.56M
Float1.19M
Held by institutions1.05%
Beta1.58
50-day MA$8.09
200-day MA$14.31
52-week high$7.50
52-week low$0.25
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-02-033.323.33+0.30%2026-01-231.611.87+16.15%2025-11-193.213.63+13.08%2025-04-07-3.00-1.20+60.00%2024-12-18-2.20-2.20+0.00%
About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead program, PrimeC, is an oral combination therapy designed for amyotrophic lateral sclerosis (ALS), while its broader pipeline includes research programs for Alzheimer’s disease and Parkinson’s disease. The company develops targeted therapeutic approaches intended to address complex neurological conditions with significant unmet medical need. NeuroSense Therapeutics Ltd. operates in the global biopharmaceutical market, where it contributes to the advancement of novel drug candidates through clinical and preclinical development. Based in Herzliya, Israel, the company is positioned within the specialized field of neuroscience-focused drug discovery and development.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alon Ben-Noon
Employees
17
Headquarters
Herzliya, Israel

Frequently asked questions about NeuroSense Therapeutics Ltd.